Abstract: A fluid delivery device (3) for a visor cleaner. The fluid delivery device (3) includes a fluid reservoir (7), which contains cleaning fluid when ready for use. The fluid delivery device (3) also includes an absorbent cleaning element (13) that is arranged to take in fluid from the reservoir (7). In use, the fluid in the reservoir (7) and the absorbent cleaning element (13) are arranged to be in permanent fluid communication.

Abstract: There is herein defined a fluid delivery device (3) for a visor cleaner. The fluid delivery device (3) includes a fluid reservoir (7), which contains cleaning fluid when ready for use. The fluid delivery device (3) also includes an absorbent cleaning element (13) that is arranged to take in fluid from the reservoir (7) by capillary action. In use, the fluid in the reservoir (7) and the absorbent cleaning element (13) are arranged to be in permanent fluid communication.

Abstract: Novel compounds of formula (I) are described wherein: R1=(CH2)mCH3 where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms; R2=H, CH3 or CH2CH3; R3=H or CH3; R4H or CH3; R5=lower alkyl having from 1 to 5 carbon atoms; n is an integer in the range from 1 to 3, and X is carboxyl (COOH) or carbalkoxy (COOR5), cyano (C?N), phosphonic acid (PO3H2), phosphonate ester (PO3[R5]2) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R— or S—configuration in which R3=R4=R5=H, R2=CH3 and R1 is a saturated aliphatic chain of one to five carbon atoms.

Abstract: Novel compounds of the formula I are described: wherein: R1=(CH2)mCH3 where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, R2=H, CH3 or CH2CH3 R3=H or CH3 R4=H or CH3 R5=lower alkyl having from 1 to 5 carbon atoms n is an integer in the range from 1 to 3, and X is carboxyl (COOH) or carbalkoxy (COOR5), cyano (C?N), phosphonic acid (PO3H2), phosphonate ester (PO3[R5]2) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R- or S-configuration in which R3=R4=R5=H, R2=CH3 and R1 is a saturated aliphatic chain of one to five carbon atoms. The compounds are useful as cellular rescue agents.

Abstract: Antineoplastic drug modulators are described. The specific modulators referred to are propargylamines which can enhance the cytotoxic effects of antineoplastic drugs on cancer cells while protecting normal cells from damage. The propargylamine modulators can be used to increase the selectivity and effectiveness of conventional antineoplastic drugs, to reduce the unwanted side-effects of cancer chemotherapy, to improve effectiveness of cancer chemotherapy, to improve treatment of cancers for which treatment is otherwise ineffective, to improve therapy of cancers otherwise unresponsive or poorly responsive due to drug-resistance and/or toxicity limited treatment regimens and to render effective chemotherapy for previously untreatable cancers.

Abstract: The present invention relates to the use of a group of propargylamines of the general formula (I) wherein R1 is hydrogen or CH3 and R2 is (CH2)nCH3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

Abstract: The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R.sup.1 is hydrogen or CH.sub.3 and R.sup.2 is (CH.sub.2).sub.n CH.sub.3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

Abstract: The invention relates to a series of propargylamines, their salts and pharmaceutical compositions containing a compound of formula (III) wherein R.sub.1, R.sub.3 and R.sub.4 are the same or different and represent hydrogen or a straight chain or branched lower alkyl; y is an integer ranging from 0 to 5; z is an integer ranging from 0 to 5; and R.sub.2 is a straight chain or branched alkyl, alkenyl, alkynyl, alkoxy, alkylthio or alkyl sulphinyl group having from 3 to 11 carbon atoms, said group being unsubstituted or substituted with at least one of the substituents selected from hydroxy, aldehyde, oxo, loweracyloxy, halogen, thio, sulfoxide, sulfone, phenyl, halogen-substituted phenyl, hydroxy-substituted phenyl, cycloalkyl having from 3 to 6 carbon atoms and heterocyclic substituents having between 3 and 6 atoms, of which form 1 to 3 are heteroatoms selected from O, S and/or N, and pharmaceutically acceptable salts thereof, in admixture with a pharmaceutically acceptable carrier, excipient or adjuvant.

Abstract: A component having the following formula I: ##STR1## wherein X represents an integer ranging from 1 to 2 or 7 to 13;Y represents an integer ranging from 0 to 5;Z represents an integer ranging from 0 to 5;R.sub.1, R.sub.2 and R.sub.3 are the same or different and represent H or a straight chain or branched lower alkyl; andR' and R" are the same or different and represent H or halogen,and pharmaceutically acceptable salts thereof. Preferably, the lower alkyl has between 1 and 4 carbon atoms and the halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine. The compound is useful as a MAO-B inhibitor. Also within the scope of the present invention is a composition for the inhibition of MAO-B activity and a method for alleviating Parkinsonism, Alzheimer's disease, depression, attention deficit hyperactive disorders, aging and other neuropsychiatric disorders and for improving the quality of life.